Literature DB >> 19109385

Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus.

Jarrod S Johnson1, R Jude Samulski.   

Abstract

Adeno-associated virus (AAV) serotypes are being tailored for numerous therapeutic applications, but the parameters governing the subcellular fate of even the most highly characterized serotype, AAV2, remain unclear. To understand how cellular conditions control capsid trafficking, we have tracked the subcellular fate of recombinant AAV2 (rAAV2) vectors using confocal immunofluorescence, three-dimensional infection analysis, and subcellular fractionation. Here we report that a population of rAAV2 virions enters the nucleus and accumulates in the nucleolus after infection, whereas empty capsids are excluded from nuclear entry. Remarkably, after subcellular fractionation, virions accumulating in nucleoli were found to retain infectivity in secondary infections. Proteasome inhibitors known to enhance transduction were found to potentiate nucleolar accumulation. In contrast, hydroxyurea, which also increases transduction, mobilized virions into the nucleoplasm, suggesting that two separate pathways influence vector delivery in the nucleus. Using a small interfering RNA (siRNA) approach, we then evaluated whether nucleolar proteins B23/nucleophosmin and nucleolin, previously shown to interact with AAV2 capsids, affect trafficking and transduction efficiency. Similar to effects observed with proteasome inhibition, siRNA-mediated knockdown of nucleophosmin potentiated nucleolar accumulation and increased transduction 5- to 15-fold. Parallel to effects from hydroxyurea, knockdown of nucleolin mobilized capsids to the nucleoplasm and increased transduction 10- to 30-fold. Moreover, affecting both pathways simultaneously using drug and siRNA combinations was synergistic and increased transduction over 50-fold. Taken together, these results support the hypothesis that rAAV2 virions enter the nucleus intact and can be sequestered in the nucleolus in stable form. Mobilization from the nucleolus to nucleoplasmic sites likely permits uncoating and subsequent gene expression or genome degradation. In summary, with these studies we have refined our understanding of AAV2 trafficking dynamics and have identified cellular parameters that mobilize virions in the nucleus and significantly influence AAV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19109385      PMCID: PMC2648275          DOI: 10.1128/JVI.02309-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

1.  Proteolytic mapping of the adeno-associated virus capsid.

Authors:  Kim Van Vliet; Veronique Blouin; Mavis Agbandje-McKenna; Richard O Snyder
Journal:  Mol Ther       Date:  2006-09-27       Impact factor: 11.454

2.  Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 3.  Intracellular distribution of proteasomes.

Authors:  A J Rivett
Journal:  Curr Opin Immunol       Date:  1998-02       Impact factor: 7.486

4.  Dynamics of proteasome distribution in living cells.

Authors:  E A Reits; A M Benham; B Plougastel; J Neefjes; J Trowsdale
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

5.  Adeno-associated virus interactions with B23/Nucleophosmin: identification of sub-nucleolar virion regions.

Authors:  Joyce M Bevington; Patrick G Needham; Kristin C Verrill; Roy F Collaco; Venkatesh Basrur; James P Trempe
Journal:  Virology       Date:  2006-09-07       Impact factor: 3.616

6.  Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus.

Authors:  Florian Sonntag; Svenja Bleker; Barbara Leuchs; Roger Fischer; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

7.  Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.

Authors:  C Summerford; R J Samulski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2.

Authors:  K Qing; C Mah; J Hansen; S Zhou; V Dwarki; A Srivastava
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

9.  AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection.

Authors:  C Summerford; J S Bartlett; R J Samulski
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

10.  A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8.

Authors:  Bassel Akache; Dirk Grimm; Xuan Shen; Sally Fuess; Stephen R Yant; Dariya S Glazer; Julie Park; Mark A Kay
Journal:  Mol Ther       Date:  2007-02       Impact factor: 11.454

View more
  70 in total

1.  Chemical Modulation of Endocytic Sorting Augments Adeno-associated Viral Transduction.

Authors:  Garrett E Berry; Aravind Asokan
Journal:  J Biol Chem       Date:  2015-11-02       Impact factor: 5.157

Review 2.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

3.  Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors.

Authors:  Angela M Mitchell; R Jude Samulski
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

4.  Probing the Link among Genomic Cargo, Contact Mechanics, and Nanoindentation in Recombinant Adeno-Associated Virus 2.

Authors:  Cheng Zeng; Sven Moller-Tank; Aravind Asokan; Bogdan Dragnea
Journal:  J Phys Chem B       Date:  2017-02-14       Impact factor: 2.991

5.  AAV-6 mediated efficient transduction of mouse lower airways.

Authors:  Wuping Li; Liqun Zhang; Zhijian Wu; Raymond J Pickles; R Jude Samulski
Journal:  Virology       Date:  2011-07-14       Impact factor: 3.616

Review 6.  Strategies to modulate immune responses: a new frontier for gene therapy.

Authors:  Valder R Arruda; Patricia Favaro; Jonathan D Finn
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

7.  Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.

Authors:  Jonathan D Finn; Daniel Hui; Harre D Downey; Danielle Dunn; Gary C Pien; Federico Mingozzi; Shangzhen Zhou; Katherine A High
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

8.  Unique characteristics of AAV1, 2, and 5 viral entry, intracellular trafficking, and nuclear import define transduction efficiency in HeLa cells.

Authors:  Nicholas W Keiser; Ziying Yan; Yulong Zhang; Diana C M Lei-Butters; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2011-06-28       Impact factor: 5.695

9.  Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain.

Authors:  Nicole K Polinski; Sara E Gombash; Fredric P Manfredsson; Jack W Lipton; Christopher J Kemp; Allyson Cole-Strauss; Nicholas M Kanaan; Kathy Steece-Collier; Nathan C Kuhn; Susan L Wohlgenant; Caryl E Sortwell
Journal:  Neurobiol Aging       Date:  2014-10-13       Impact factor: 4.673

10.  Adeno-associated virus capsid antigen presentation is dependent on endosomal escape.

Authors:  Chengwen Li; Yi He; Sarah Nicolson; Matt Hirsch; Marc S Weinberg; Ping Zhang; Tal Kafri; R Jude Samulski
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.